Mutated IDH1 is a favorable prognostic factor for type 2 gliomatosis cerebri

Brain Pathology

Volumn 22, Issue 3, 2012, Pages 307-317

  Kwon, Mi Jung ^a   Kim, Sung Tae ^c   Kwon, Mi Jeong ^b   Kong, Doo Sik ^c   Lee, Dageun ^c   Park, Sanghui ^d   Kang, So Young ^c   Song, Ji Young ^c   Nam, Do Hyun ^c   Kato, Yukinari ^e   Choi, Yoon La ^c   Suh, Yeon Lim ^c  

^a Hallym University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Gachon University College of Medicine   (South Korea)

^e YAMAGATA UNIVERSITY   (Japan)

Author keywords

Gliomatosis cerebri; IDH1; IDH2; Mutations; Prognostic factor

Indexed keywords

ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE ISOENZYME; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DISEASE COURSE; FEMALE; GENE MUTATION; GLIOMA; GLIOMATOSIS CEREBRI; GLIOSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PREDICTIVE VALUE; PRESCHOOL CHILD; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN METHYLATION; SCHOOL CHILD; SEQUENCE ANALYSIS; TUMOR GROWTH;

ADOLESCENT; ADULT; AGED; BRAIN; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; ISOCITRATE DEHYDROGENASE; MALE; MIDDLE AGED; MUTATION; NEOPLASMS, NEUROEPITHELIAL; PROGNOSIS; SURVIVAL RATE;

EID: 84859800560     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2011.00532.x     Document Type: Article

References (29)

1. Bonavia R, Inda MD, Cavenee WK, Furnari FB (2011) Heterogeneity maintenance in glioblastoma: a social network. Cancer Res 71:4055-4060.
2. Capper D, Weissert S, Balss J, Habel A, Meyer J, Jager D et al (2009) Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol 20:245-254.
3. Desclee P, Rommel D, Hernalsteen D, Godfraind C, de Coene B, Cosnard G (2010) Gliomatosis cerebri, imaging findings of 12 cases. J Neuroradiol 37:148-158.
4. Desestret V, Ciccarino P, Ducray F, Criniere E, Boisselier B, Labussiere M et al (2011) Sanson M Prognostic stratification of gliomatosis cerebri by IDH1(R132H) and INA expression. J Neurooncol 105:219-224.
5. Felsberg J, Wolter M, Seul H, Friedensdorf B, Goppert M, Sabel MC (2010) Reifenberger G Rapid and sensitive assessment of the IDH1 and IDH2 mutation status in cerebral gliomas based on DNA pyrosequencing. Acta Neuropathol 119:501-507.
6. Fuller GN, Kros JM (2007) Gliomatosis cerebri. In: WHO Classification of Tumours of the Central Nervous System, DN Louis, H Ohgaki, ODWiestler, WK Cavenee (eds), pp. 50-52. IARC Press: Lyon.
7. Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S et al (2007) The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess 11:iii-iiv. ix-221.
8. Gerber DE, Grossman SA, Zeltzman M, Parisi MA, Kleinberg L (2007) The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas. Neuro Oncol 9:47-52. (Pubitemid 46543488)
9. Glas M, Bahr O, Felsberg J, Rasch K, Wiewrodt D, Schabet M et al (2011) NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri. Ann Neurol 70:445-453.
10. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A et al (2009) Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 118:469-474.
11. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M et al (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003. (Pubitemid 40349502)
12. Inoue T, Kumabe T, Kanamori M, Sonoda Y, Watanabe M, Tominaga T (2010) Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases. Neurosurg Rev 34:197-208.
13. Jennings MT, Frenchman M, Shehab T, Johnson MD, Creasy J, LaPorte K, Dettbarn WD (1995) Gliomatosis cerebri presenting as intractable epilepsy during early childhood. J Child Neurol 10:37-45.
14. Kaloshi G, Everhard S, Laigle-Donadey F, Marie Y, Navarro S, Mokhtari K et al (2008) Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri. Neurology 70:590-595. (Pubitemid 351294636)
15. Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, Bigner DD (2009) A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun 390:547-551.
16. Kattar MM, Kupsky WJ, Shimoyama RK, Vo TD, Olson MW, Bargar GR, Sarkar FH (1997) Clonal analysis of gliomas. Hum Pathol 28:1166-1179. (Pubitemid 27446603)
17. Mawrin C, Kirches E, Schneider-Stock R, Scherlach C, Vorwerk C, Von Deimling A et al (2003) Analysis of TP53 and PTEN in gliomatosis cerebri. Acta Neuropathol 105:529-536. (Pubitemid 36798851)
18. Narasimhaiah D, Miquel C, Verhamme E, Desclee P, Cosnard G, Godfraind C (2011) IDH1 mutation, a genetic alteration associated with adult gliomatosis cerebri. Neuropathology [Epub ahead of Print].
19. Nevin S (1938) Gliomatosis cerebri. Brain 61:170-191.
20. Park S, Suh YL, Nam DH, Kim ST (2009) Gliomatosis cerebri: clinicopathologic study of 33 cases and comparison of mass forming and diffuse types. Clin Neuropathol 28:73-82.
21. Sanson M, Cartalat-Carel S, Taillibert S, Napolitano M, Djafari L, Cougnard J et al (2004) Initial chemotherapy in gliomatosis cerebri. Neurology 63:270-275. (Pubitemid 38971125)
22. Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F et al (2009) Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol 27:4150-4154.
23. Seiz M, Tuettenberg J, Meyer J, Essig M, Schmieder K, Mawrin C et al (2010) Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes. Acta Neuropathol 120:261-267.
24. Shapiro JR, Yung WK, Shapiro WR (1981) Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cancer Res 41:2349-2359. (Pubitemid 11111441)
25. Takano S, Tian W, Matsuda M, Yamamoto T, Ishikawa E, Kaneko MK et al (2011) Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol 28:115-123.
26. van Nifterik KA, van den Berg J, van der Meide WF, Ameziane N, Wedekind LE, Steenbergen RD et al (2010) Absence of the MGMT protein as well as methylation of the MGMT promoter predict the sensitivity for temozolomide. Br J Cancer 103:29-
27. Villano JL, Seery TE, Bressler LR (2009) Temozolomide in malignant gliomas: current use and future targets. Cancer Chemother Pharmacol 64:647-655.
28. Wikstrand CJ, Bigner SH, Bigner DD (1983) Demonstration of complex antigenic heterogeneity in a human glioma cell line and eight derived clones by specific monoclonal antibodies. Cancer Res 43:3327-3334. (Pubitemid 13061594)
29. Yen KE, Bittinger MA, Su SM, Fantin VR (2010) Cancer-associated IDH mutations: biomarker and therapeutic opportunities. Oncogene 29:6409-6417.